Brief: Satsuma Pharmaceuticals Announces Topline Results From Emerge Phase 3 Trial Of Sts101 For The Acute Treatment Of Migraine

Satsuma Pharmaceuticals

10/09/2020 14:59

Sept 10 (Reuters) - Satsuma Pharmaceuticals Inc  STSA.O :
    * SATSUMA PHARMACEUTICALS ANNOUNCES TOPLINE RESULTS FROM
EMERGE
PHASE 3 TRIAL OF STS101 FOR THE ACUTE TREATMENT OF MIGRAINE
    * SATSUMA - TOPLINE DATA DID NOT SHOW STATISTICALLY
SIGNIFICANT
DIFFERENCES BETWEEN EITHER DOSAGE STRENGTH OF STS101 AND PLACEBO
ON CO-PRIMARY ENDPOINTS
    * SATSUMA PHARMACEUTICALS INC - STS101 WAS WELL-TOLERATED IN
THIS
TRIAL WITH LOW ADVERSE EVENT RATES AND NO SERIOUS ADVERSE EVENTS
REPORTED
    * SATSUMA PHARMACEUTICALS INC - FURTHER ANALYSES OF EMERGE
TRIAL
DATA ARE ONGOING
    * SATSUMA PHARMACEUTICALS INC - AS OF JUNE 30, 2020, COMPANY
HAD
CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $93.7
MILLION

Source text for Eikon:  ID:nGNXxs7mL 
Further company coverage:  STSA.O 

 ((Reuters.Briefs@thomsonreuters.com;))